Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 21,991 matching trials from the live ClinicalTrials.gov search.

Filters: Recruiting Clear all

Conditions: Aging
Interventions: High-Intensity Interval Training (HIIT) Breaks to Sitting, Light-Intensity Interval Training (LIIT) Breaks to Sitting; Behavioral
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 40 Years to 75 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Urbana, Illinois

Conditions: Other Skin Changes Due to Chronic Exposure to Nonionizing Radiation
Interventions: Solar Simulated Light; Other
Lead sponsor: University of Arizona; Other
Eligibility: 40 Years and older
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Diabetes Mellitus, Type 2, End Stage Renal Disease, Irritable Bowel Syndrome
Interventions: None (Observational); Other
Lead sponsor: Indiana University; Other
Eligibility: 12 Years to 99 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Hepatic Impairment, Healthy, Hepatic Insufficiency, Healthy Adults
Interventions: Atirmociclib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Miami Lakes, Florida • Orlando, Florida • Tampa, Florida

Conditions: Allergies, Food Allergy
Interventions: 5mg/kg omalizumab injection, 15mg/kg omalizumab injection; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 1 Year to 55 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Boston, Massachusetts • Chapel Hill, North Carolina • Dallas, Texas

Conditions: Fatty Liver, Hepatic Steatosis
Interventions: Photon-counting CT (PCCT), Ultrasound, Magnetic Resonance Imaging (MRI); Diagnostic Test
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Breast Biopsy, Anxiety, Pain
Interventions: Virtual Reality (VR) Mindful App, Standard Calming Music; Other
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Mucopolysaccharidosis IIIB
Interventions: JR-446; Drug
Lead sponsor: JCR Pharmaceuticals Co., Ltd.; Industry
Eligibility: Up to 5 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Oakland, California • Pittsburgh, Pennsylvania • Fairfax, Virginia

Conditions: Feeding Difficulties, Aspiration, Gastrostomy
Interventions: amino acid based formula (e.g. Elecare Jr), low bile acid binding blenderized diet (e.g. Kate Farms), high bile acid binding blenderized diet; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 5 Years to 21 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Tobacco Use Disorder
Interventions: Cognitive Behavioral Therapy (CBT), Cue-based treatment intervention; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Clinical High Risk, Early Psychosis, First Episode Psychosis
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: 12 Years to 29 Years
Enrollment: 25,000 participants
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Depression / Major Depressive Disorder, Food Insecurity
Interventions: Medically Tailored, Home-delivered Groceries, Active Comparison Group: Monthly Grocery Gift Card; Other
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: Worcester, Massachusetts

Conditions: Autism Spectrum Disorder, Mitochondrial Pathology, Epilepsy, Brain Tumor, Psychiatric Disorder, Mitochondrial Diseases
Interventions: Not listed
Lead sponsor: Southwest Autism Research & Resource Center; Other
Eligibility: Up to 18 Years
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: Phoenix, Arizona • Brooklyn, New York

Conditions: Major Depressive Disorder
Interventions: Ketamine, Esketamine; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Triple Negative Breast Cancer, HER2-negative Breast Cancer, Non Small Cell Lung Cancer, Cervical Cancer, Castrate Resistant Prostate Cancer, Pancreatic Ductal Adenocarcinoma, Head-and-neck Squamous Cell Carcinoma, Endometrial Cancer, Ovarian Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Urothelial Carcinoma
Interventions: DR-0202; Drug
Lead sponsor: Dren Bio; Industry
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 10
States / cities: Denver, Colorado • Orlando, Florida • Sarasota, Florida + 7 more

Conditions: Metastatic Breast Cancer
Interventions: Estradiol; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Graves' Disease, Graves Disease
Interventions: Efgartigimod PH20 SC, Placebo PH20 SC; Biological · Other
Lead sponsor: argenx; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 29
States / cities: Carlsbad, California • Orange, California • Pasadena, California + 24 more

Conditions: Syphilis
Interventions: Rapid Point of Care (POC) Syphilis testing; Device
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Secondary Progressive Multiple Sclerosis (SPMS)
Interventions: Remibrutinib (blinded), Placebo, Remibrutinib (Open label); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 43
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 35 more

Conditions: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Tardive Dyskinesia
Interventions: Valbenazine; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 19
States / cities: Bryant, Arkansas • Chino, California • Fresno, California + 16 more

Conditions: Overactive Bladder (OAB), Urge Incontinence
Interventions: onabotulinum toxin type a; Drug
Lead sponsor: Alexis Dieter; Other
Eligibility: 55 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Gastrointestinal
Interventions: Synbiotic Dietary Supplement, Placebo; Dietary Supplement
Lead sponsor: OvationLab; Network
Eligibility: 25 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Stenosis Trachea
Interventions: The truFreeze Spray Cryotherapy, Ballon dilation, Radial Incision; Device
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Adenocarcinoma of the Pancreas
Interventions: Hydroxychloroquine sulfate; Drug
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 1
States / cities: Morgantown, West Virginia

Search by objective public record fields.

Breaking Sitting with High-intensity Interval Training for Brain Health

SUV PDL1/PD1 in Sun Damaged & Sun Protected Human Skin of Participants

Drug Interaction Potential of Pro-Inflammatory Conditions

A Study to Learn How the Study Medicine Called Atirmociclib is Handled by the Body in People With Normal Liver Function and Different Levels of Liver Disease

Omalizumab Weight-Based Dosing Efficacy Trial

Siemens Biomarker Multi-modality

Virtual Reality vs. Music Relaxation for Reducing Anxiety and Pain During Breast Biopsies

A Phase I/II Trial of JR-446 in Mucopolysaccharidosis Type IIIB (MPS IIIB)

The Use of High Bile-binding Foods to Reduce Upper Gastrointestinal Bile Acid Concentrations (Aim 1)

Project Q: Cue-based Treatment Intervention to Promote Cessation Among People Who Smoke Lightly or Non-daily

Digital Strategies to Advance Help-Seeking Aim 1 and 2

The Medically Tailored Groceries and Mental Health Study

Transgenerational Metabolic-Immune Biomarkers of Neurological and Neurodevelopmental Disorders

Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER)

A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease

Offering Routine and Rapid Point of Care (POC) Syphilis Testing in Pregnant Patients Presenting to the Emergency Department

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

Assessing the Genitourinary Microbiome of Women With Overactive Bladder Undergoing Onabotulinum Toxin Type A Intradetrusor Injections

Terraflora Daily Care and Gastrointestinal Health

Cryospray Therapy for Benign Airway Stenosis

Neoadjuvant mFOLFIRINOX With Perioperative Oral Hydroxychloroquine in Resectable Pancreatic Adenocarcinoma